Central Trust Company’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Central Trust Company’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$34.2K	Buy	+535	New	+$27.8K	﹤0.01%	956

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Central Trust Company's KNSA Position: Q2 2026 in Review

Central Trust Company opened a new position in Kiniksa Pharmaceuticals (KNSA) in Q2 2026: 535 shares worth $34.2K. The stake represents ﹤0.01% of the portfolio and ranks #956 among its holdings.

266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

Central Trust Company held 535 shares of Kiniksa Pharmaceuticals worth $34.2K as of Q2 2026.
Kiniksa Pharmaceuticals was a new Central Trust Company position in Q2 2026.
Kiniksa Pharmaceuticals made up ﹤0.01% of Central Trust Company's portfolio in Q2 2026, its #956 holding.
266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Central Trust Company's 13F filing for Q2 2026, filed 31 Jul 2026.